FAP与FDG PET/CT在不同癌症中检测性能的比较:系统综述与Meta分析
该Meta分析纳入30项研究共1170例患者,比较FAP与FDG PET/CT对原发肿瘤、复发肿瘤、淋巴结转移及远处转移的检测率。FAP检测原发肿瘤、淋巴结转移和远处转移的灵敏度(0.84-0.98)、诊断比值比(19.36-358.47)及SROC曲线下面积(0.94-0.99)优于FDG,但FAP在泌尿系统肿瘤中摄取低于FDG,且FAP对原发肿瘤特异性低。
要点
- FAP对原发肿瘤、淋巴结转移及远处转移的灵敏度、诊断比值比和SROC均优于FDG。
- FAP在原发肿瘤中胰腺癌摄取最浓,其次为头颈、宫颈、结直肠、肺、胃及肝细胞癌。
- FAP在泌尿系统肿瘤中摄取低于FDG,且对原发肿瘤特异性低。
核心结论
- FAP是极有潜力替代肿瘤学中大部分FDG使用的放射性示踪剂。
- FAP示踪剂对原发肿瘤灵敏度极好但特异性低,且在泌尿系统肿瘤中摄取低于FDG。
- FAP与FDG对肉瘤淋巴结转移检测的差异无法确定。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE和Cochrane图书馆数据库,更新至2022年4月30日。
- 共纳入30项研究、1170例患者,计算FAP与FDG的检测率、相对风险及SUVmax,并分析灵敏度、特异度、诊断比值比及SROC曲线。
主要发现
- FAP对原发肿瘤、复发肿瘤、淋巴结转移和远处转移的检测率相对风险为FDG的1.06至3.00倍(按患者和按病灶)。
- 原发肿瘤中FAP摄取在胰腺癌最浓,其次为头颈、宫颈、结直肠、肺、胃及肝细胞癌,除泌尿系统肿瘤外均高于FDG。
- FAP基于患者和病灶的灵敏度(0.84-0.98)、诊断比值比(19.36-358.47)及SROC曲线(0.94-0.99)在原发肿瘤、淋巴结转移和远处转移均优于FDG。
关键数值与推荐
- FAP对原发肿瘤、淋巴结转移及远处转移的灵敏度为0.84-0.98,诊断比值比为19.36-358.47,SROC曲线为0.94-0.99。
临床怎么用
- 原文未据此给出推荐。
局限性
- FAP示踪剂对原发肿瘤虽灵敏度极好但特异性低。
- FAP在泌尿系统肿瘤中摄取低于FDG。
- FAP与FDG对肉瘤淋巴结转移检测的差异无法确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-FDG is the dominant radiotracer in oncology; however, it has limitations. Novel labeled fibroblast activation protein (FAP) radiotracers have been developed and published in several studies. Thus, this meta-analysis aimed to compare the detection rates (DRs) of FDG and FAP, based on previous studies from a systematic review. METHODS: PubMed/MEDLINE and Cochrane library databases were used to perform a comprehensive and systematic search and are updated to April 30, 2022. The DR, relative risk, and the SUVmax were calculated between the FAP and FDG tracers. Finally, the sensitivity, specificity, diagnostic odds ratio, and summary receiver operating characteristic curve of FAP and FDG were analyzed using gold and reference standards. RESULTS: Thirty studies (1170 patients) were included in the meta-analysis. The relative risks of FAP DR for the primary tumor, recurrent tumor, lymph node metastasis, and distant metastasis were FDG 1.06- to 3.00-fold per patient and per lesion. For the primary tumor, FAP uptake was most intense in pancreatic cancer, followed by head and neck, cervical, colorectal, lung, gastric, and hepatocellular carcinoma, and was higher than FDG except for urological system cancer. The sensitivity (0.84-0.98), diagnostic odds ratio (19.36-358.47), and summary receiver operating characteristic curve (0.94-0.99) of FAP based on patient and lesion were better for primary tumors, LN metastasis, and distant metastasis than FDG. CONCLUSIONS: Fibroblast activation protein is an extremely potential radiotracer to replace most of the use of FDG in oncology. It is noteworthy that the FAP tracers for primary tumors had low specificity despite excellent sensitivity and had lower uptake than FDG in urological system cancer. In addition, the difference in detection between FAP and FDG for LN metastasis could not be certain in sarcoma.
引用
- Chang WY, Tseng NC, Chen LY, et al. Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers: A Systemic Review and Meta-analysis. Clin Nucl Med. 2022. PMID: 36607362. doi:10.1097/RLU.0000000000004438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。